The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to $11.90 / share. This is an increase of 25.00% from the prior estimate of $9.52 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $10.10 to a high of $13.65 / share. The average price target represents an increase of 176.10% from the latest reported closing price of $4.31 / share.
What is the Fund Sentiment?
There are 80 funds or institutions reporting positions in X4 Pharmaceuticals. This is an decrease of 5 owner(s) or 5.88% in the last quarter. Average portfolio weight of all funds dedicated to XFOR is 0.84%, an increase of 869.30%. Total shares owned by institutions increased in the last three months by 522.36% to 85,843K shares.
What are Other Shareholders Doing?
Empery Asset Management holds 8,951K shares representing 9.85% ownership of the company.
Bain Capital Life Sciences Investors holds 7,967K shares representing 8.76% ownership of the company. In its prior filing, the firm reported owning 2,437K shares , representing an increase of 69.42%. The firm increased its portfolio allocation in XFOR by 341.33% over the last quarter.
Perceptive Advisors holds 6,314K shares representing 6.95% ownership of the company.
Saturn V Capital Management holds 5,801K shares representing 6.38% ownership of the company.
Deep Track Capital holds 5,014K shares representing 5.51% ownership of the company. In its prior filing, the firm reported owning 1,122K shares , representing an increase of 77.61%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
